Nicholas Lydon, Director at Blueprint Medicines Corp (BPMC), sold 70,000 shares at $40.06 ($2.8M) on 2017-03-14, disclosed to the SEC on 2017-03-16.
Open-market sale of $2.8M BPMC by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.72 | 1,400 | $56K | 2.0% |
| 2 | $40.06 | 68,600 | $2.7M | 98.0% |
| Total | $40.05 avg | 70,000 | $2.8M | 100% |
| Filing → |
| BPMC | SELL | 2020-07-08 | $4.1M | — | Filing → |
| BPMC | SELL | 2020-07-06 | $661K | — | Filing → |
| BPMC | SELL | 2020-06-25 | $32K | — | Filing → |